Lonza is expanding its mammalian drug substance manufacturing facilities in Visp, Switzerland and Portsmouth, U.S. In Visp, a new large-scale mammalian drug substance manufacturing facility will expand capacity with six 20,000L bioreactors and will have an area of approximately 27,500 m2.   The investment will increase large-scale biologics manufacturing capacity to meet customer demand in the contract manufacturing space. The high throughput facility includes perfusion capabilities and is des...